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Abstract: Background  
 
Evidence regarding the utility of imaging studies in selecting patients 
for endovascular thrombectomy (EVT) is limited. We aimed to investigate 
baseline-imaging features associated with efficacy and safe-ty of 
endovascular thrombectomy (EVT) in acute ischaemic stroke caused by 
anterior large vessel occlusion. 
 
Methods  
 
The HERMES (Highly Effective Reperfusion evaluated in Multiple 
Endovascular Stroke Trials) Collaboration identified 7 randomized 
endovascular stroke trials listed in PubMed from 1/Jan/2010 to 
31/October/2017 as comparing EVT to standard medical therapy. Only trials 
that required vessel imaging to identify patients with proximal anterior 
circulation ischemic stroke and used predominantly stent retrievers or 
second-generation neuro-thrombectomy devices in the EVT arm were 
included. The risk of bias was assessed using the Cochrane tool and was 
low except in the THRACE study that employed un-blinded assessment of 90-
day outcome and MRI predominantly as the primary baseline imaging tool.  
Central, blinded readers rated baseline imaging for ischemic change using 
the Alberta Stroke Program Early Computed Tomography score (ASPECTS) or 
ischemic change involving > 1/3 of middle cerebral artery territory, 
thrombus volume, hyperdensity, and collateral status. Primary endpoint 
was the modified Rankin Scale (mRS) score at 90 days. Safety outcomes 
included symptomatic intracranial hemorrhage (sICH) , parenchymal 
hematoma type 2 (PH2)  within 5 days of randomization, and mortality 
within 90 days. 
Primary analysis used mixed methods ordinal logistic regression adjusted 
for age, sex, NIHSS score at admission, intravenous alteplase and time 
from onset to randomization and interaction terms to test if imaging 
categorization at baseline modifies the relationship between treatment 
and outcome. 
 
Findings  
Among 1764 pooled patients, 871 were allocated to the EVT arm and 893 to 
control. The overall treatment effect favored EVT (adjusted common Odds 
Ratio for a shift towards better outcome on the mRS 2·00, 95% CI 1·69-
2·38; p<0·0001). EVT achieves better 90 day outcomes than medical thera-
py alone across a broad range of baseline imaging categories including in 
patients with low AS-PECTS 0-4 (adjusted common Odds Ratio 2·15, 95% CI 
1·06-4·37, interaction P= 0·054), > 1/3 MCA territory infarct (adjusted 
common Odds Ratio 1·70, 95% CI 1·04-2·78, interaction P= 0·262), poor 
collaterals (adjusted common Odds Ratio 1·49, 95% CI 0·86-2·55, 
interaction P= 0·296) and all levels of clot burden (interaction P= 
0·050). 
No treatment effect modification by baseline imaging features was noted 
for 90-day-mortality and PH2. Higher risk of sICH was seen in patients 
with ASPECTS 0-4 (19·2% versus 4·5%, adjusted common Odds Ratio 3·94, 95% 
CI 0·94-16·49, interaction P= 0·025) and with > 1/3 MCA territory infarct 
(13·9% versus 3·5%, adjusted common Odds Ratio 4·17, 95% CI 1·3-13·44, 
interaction P=0·012) when allocated EVT. 
 
Interpretation  
EVT achieves better 90-day outcomes than control across a broad range of 
baseline imaging catego-ries. This analysis provides evidentiary support 
to expand existing practice guidelines to provide EVT, in a qualified 
manner, even in patients with large infarcts at baseline.  
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SUMMARY  
 
Background  
 
Evidence regarding the utility of imaging studies in selecting patients for endovascular 
thrombectomy (EVT) is limited. We aimed to investigate baseline-imaging features associated with 
efficacy and safety of endovascular thrombectomy (EVT) in acute ischaemic stroke caused by ante-
rior large vessel occlusion. 
 
Methods  
 
The HERMES (Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials) 
Collaboration identified 7 randomized endovascular stroke trials listed in PubMed from 1/Jan/2010 
to 31/October/2017 as comparing EVT to standard medical therapy. Only trials that required vessel 
imaging to identify patients with proximal anterior circulation ischemic stroke and used 
predominantly stent retrievers or second-generation neuro-thrombectomy devices in the EVT arm 
were included. The risk of bias was assessed using the Cochrane tool and was low except in the 
THRACE study that employed un-blinded assessment of 90-day outcome and MRI predominantly 
as the primary baseline imaging tool.  Central, blinded readers rated baseline imaging for ischemic 
change using the Alberta Stroke Program Early Computed Tomography score (ASPECTS) or 
ischemic change involving > 1/3 of middle cerebral artery territory, thrombus volume, 
hyperdensity, and collateral status. Primary endpoint was the modified Rankin Scale (mRS) score at 
90 days. Safety outcomes included symptomatic intracranial hemorrhage (sICH) , parenchymal 
hematoma type 2 (PH2)  within 5 days of randomization, and mortality within 90 days. 
Primary analysis used mixed methods ordinal logistic regression adjusted for age, sex, NIHSS score 
at admission, intravenous alteplase and time from onset to randomization and interaction terms to 
test if imaging categorization at baseline modifies the relationship between treatment and outcome. 
 
Findings  
Among 1764 pooled patients, 871 were allocated to the EVT arm and 893 to control. The overall 
treatment effect favored EVT (adjusted common Odds Ratio for a shift towards better outcome on 
the mRS 2·00, 95% CI 1·69–2·38; p<0·0001). EVT achieves better 90 day outcomes than medical 
therapy alone across a broad range of baseline imaging categories including in patients with low 
ASPECTS 0-4 (adjusted common Odds Ratio 2·15, 95% CI 1·06–4·37, interaction P= 0·054), > 1/3 
MCA territory infarct (adjusted common Odds Ratio 1·70, 95% CI 1·04–2·78, interaction P= 
0·262), poor collaterals (adjusted common Odds Ratio 1·49, 95% CI 0·86–2·55, interaction P= 
0·296) and all levels of clot burden (interaction P= 0·050). 
No treatment effect modification by baseline imaging features was noted for 90-day-mortality and 
PH2. Higher risk of sICH was seen in patients with ASPECTS 0-4 (19·2% versus 4·5%, adjusted 
common Odds Ratio 3·94, 95% CI 0·94–16·49, interaction P= 0·025) and with > 1/3 MCA territory 
infarct (13·9% versus 3·5%, adjusted common Odds Ratio 4·17, 95% CI 1·3–13·44, interaction 
P=0·012) when allocated EVT. 
 
Interpretation  
EVT achieves better 90-day outcomes than control across a broad range of baseline imaging catego-
ries. This analysis provides evidentiary support to expand existing practice guidelines to provide 
EVT, in a qualified manner, even in patients with large infarcts at baseline.  
 
 
Funding Unrestricted grant from Medtronic. 
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Research in context   
 
Evidence before the study: 
 
Recent randomized trials have demonstrated the efficacy of endovascular thrombectomy (EVT). 
The Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials (HERMES) 
collaboration published in Feb 2016 a pooled analysis of individual patient-level data of the first 
five randomized trials of endovascular thrombectomy. It confirmed benefit of endovascular 
thrombectomy across a wide range of clinical subgroups and reported on the effect of ASPECTS 
and site of vessel occlusion as assessed by each individual trial. However, evidence regarding utility 
of imaging in selecting patients for EVT is limited. 
                                                                                     
 Added value of this study  
 
This is the first individual level meta-analysis using imaging data obtained through single core lab 
analysis from all seven randomized endovascular stroke trials listed in PubMed (1/Jan/2010-
31/October/2017) comparing EVT to standard medical therapy in patients with acute ischemic 
stroke and anterior circulation large vessel occlusion. Trials requiring imaging to identify patients 
with anterior circulation ischemic stroke and using second-generation neuro-thrombectomy devices 
in the EVT arm were included. It represents a unique dataset that is unlikely to ever be replicated in 
the future, as randomized trials of thrombectomy for large vessel occlusion stroke in the patient 
population studied by these trials are no longer considered ethically justifiable. This meta-analysis 
provides new and substantial evidence that patients with a broad range of baseline imaging 
characteristics including those with larger infarcts, poor collaterals and any clot burden score 
benefit from endovascular thrombectomy (EVT).   
     
Implications of all the available evidence 
Current guidelines by the American Heart Association (AHA) recommend EVT in patients with 
ASPECTS>5. This analysis provides evidentiary support for expansion of existing practice guide-
lines to endorse, in a qualified manner, EVT even for patients with large infarcts at baseline (AS-
PECTS as low as 3). 
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INTRODUTION 
Recent randomized clinical trials have established the efficacy and safety of endovascular 
thrombectomy (EVT) in the treatment of patients with acute ischemic stroke and proximal anterior 
circulation occlusion.
1-8
 Because clinical benefit observed in these trials is time dependent, the need 
for fast and efficient patient selection is well recognized.
9
 Imaging is widely used to determine 
prognosis and to select patients for EVT.
10-12
 After the results of the five trials reported in 2015, the 
new AHA guidelines recommend EVT as standard of care (Level I, Class A evidence) in patients 
with baseline non-contrast CT ASPECTS 6-10.
13
 
 
Imaging features are strong predictors of clinical outcome.
10
 Large infarcts at baseline, large 
thrombus in proximal arteries and poor collateral circulation identified using imaging are overall 
associated with lower likelihood of functional dependence and increased risk after reperfusion 
therapies.
14-19
 However, evidence regarding the utility of these imaging features in selecting patients 
for EVT is limited. This patient level meta-analysis of the HERMES (Highly Effective Reperfusion 
evaluated in Multiple Endovascular Stroke Trials) Collaboration aims to determine baseline-
imaging features associated with efficacy and safety of EVT when compared to standard medical 
therapy.  
 
 
METHODS 
Study design and participants  
We searched Pubmed for randomized trials published between 1 Jan 2010 and 31 October 2017 
comparing endovascular thrombectomy performed using predominantly stent-retrievers with stand-
ard care in anterior circulation ischaemic stroke patients - Pubmed search string: (("randomized 
controlled trial"[Publication Type]) AND ((thrombectomy [Title/Abstract]) OR (clot retrieval [Ti-
tle/Abstract]) OR intraarterial[Title/Abstract]) AND (stroke[Title/Abstract]) AND 
("2010/01/01"[Date - Publication] : "2017/10/31"[Date - Publication])). 
The HERMES (Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials) 
Collaboration pooled patient level demographic, clinical and imaging data as well as functional and 
radiologic outcomes from 7 randomized trials: MR CLEAN, ESCAPE, EXTEND-IA, SWIFT 
PRIME, REVASCAT, THRACE and PISTE  (Supplement eFigure 1). All these trials required ves-
sel imaging to identify patients with anterior circulation ischemic stroke and used predominantly 
stent retrievers or second-generation neuro-thrombectomy devices in the EVT arm. Data were as-
sessed for quality and validity using PRISMA guidelines. Differences in patient population, sam-
pling frame and operational definitions of intervention (EVT) and control were assessed before col-
lating all data at a patient level (Supplement eTable 1). Risk of bias in the individual studies was 
assessed using the Cochrane handbook methodology and was low overall except in the THRACE 
study that used un-blinded assessment of 90-day outcome. In addition, in contrast to other studies, 
the THRACE study used MRI predominantly as the primary baseline imaging tool. This meta-
analysis was prospectively designed by the HERMES executive committee but not registered. All 
participants provided informed consent according to each trial protocol and each study was ap-
proved by the local ethics board. The methodological design for this patient level pooling has been 
previously described.
8
  
Imaging variables 
Baseline images included information available either on Computed Tomography (CT) or on 
Magnetic Resonance Imaging (MRI). All imaging studies were de-identified at the HERMES 
central coordinating center. The imaging datasets were then read by independent HERMES core 
labs for baseline CT/MRI, baseline CT Angiography (CTA), MRI Angiography (MRA), follow up 
CT or MR, and conventional angiography. Readers were blinded to all clinical information, except 
side of stroke.  
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Imaging in acute ischemic stroke is used to identify extent of early ischemic change and location 
and extent of thrombus. Pre-specified baseline imaging features of interest therefore were:  
1. The Alberta Stroke Program Early CT Score (ASPECTS) defined on CT or MR Diffusion 
Weighted Imaging (MR-DWI). This widely used ordinal scale measures extent of ischemia 
in the middle cerebral artery (MCA) territory (from score 0 in complete infarction to 10 for 
no infarction) .20 An ASPECTS region was considered as involved on DWI if the lesion 
occupied > 30% of the respective region, and on CT if any signs of ischemia were visible on 
at least two consecutive cuts of the 10 standardized regions of the MCA territory. ASPECTS 
grading was evaluated independently by experts blinded to all clinical and imaging 
information except stroke side. Any disagreement was resolved by consensus. 
Trichotomized ASPECTS agreement between two raters (JB, LSR) assessed in 30 patients 
using weighted kappa was good (kappa 0.89, 95% CI 0.81 -0.99. 
2. The > 1/3rd MCA rule defined on CT or MR-DWI as early ischemic change in > 1/3rd of the 
ischemic MCA territory.
21
 
3. Thrombus location identified on CTA or MRA. Thrombus location was classified as that in 
the intracranial internal carotid artery (ICA), proximal M1 middle cerebral artery (MCA) 
segment, distal M1 MCA segment and M2 MCA segment. Tandem occlusion was defined as 
thrombus in extracranial ICA along with intracranial (ICA, M1-MCA, M2-MCA) 
thrombus.
22 
4. Collateral circulation distal to intracranial thrombus. Collateral circulation was evaluated on 
multi-phase CTA, single phase CTA or contrast-enhanced MRA and classified according to 
a previously published pre-specified collateral grade category (grade 0-1, poor; grade 2, 
intermediate; grade 3, good).
19 
5. Thrombus density on imaging identified using assessment of the hyperdense artery sign on 
CT 23 and thrombus volume on CTA, analyzed using the clot burden score (CBS).
24 
Data on number of patients assessed for each imaging variable at baseline and reasons for exclusion 
are described in Supplement eTable 2. Patients were excluded from further analyses if images were 
unavailable from primary trial or were of poor quality. 
 
Outcomes 
The primary endpoint was neurological functional disability scored on the modified Rankin Scale 
(mRS) 90 days after randomization with categories 5 (severe disability) and 6 (death) collapsed into 
a single category. Secondary efficacy outcomes were functional independence (mRS 0–2) at 90 
days, excellent functional outcome (mRS 0–1) at 90 days and dramatic neurological improvement 
(defined as neurological improvement of ≥ 8 points in the NIHSS or a NIHSS 0-1 24 hours after 
stroke). Safety outcomes included intracranial hemorrhage defined as both symptomatic intracranial 
hemorrhage (sICH; defined by each trial), parenchymal hematoma type 2 (PH2; blood clot 
occupying >30% of the infarcted territory with substantial mass effect) within 5 days of 
randomization, and mortality within 90 days. 
 
Statistical analysis 
All analyses were based on the “as randomized” population. Unless otherwise stated, all reported 
analyses were pre-specified in the Statistical Analysis Plan. (Supplementary Material) To account 
for between trial differences when pooling patient level data, mixed-effects modeling was used for 
all analyses, with fixed effects for parameters of interest and “trial” and the interaction term 
“trial*treatment” as random effects variables in all models.8 Ordinal logistic regression models 
included fixed effects (age, sex, NIHSS score at admission, intravenous alteplase use and time from 
onset to randomization) and multiplicative interaction terms to test if pre-specified baseline-imaging 
features modified the effect of treatment allocation on pre-defined outcomes.  ASPECTS scores 
were trichotomized as 0-4, 5-7 and 8-10 for primary analysis.  In addition, as pre-specified in the 
Statistical Analysis Plan, an attempt was made to analyze treatment effect across each ASPECTS 
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grade to identify an ASPECTS grade below which endovascular treatment may be considered futile 
or potentially harmful.
13
 Sensitivity analyses were performed according to the primary imaging 
modality (CT or MRI) used at baseline. When missing (n= 21), the primary outcome was imputed 
as per methods pre-specified in each of the trials. All statistical analyses were performed using SAS 
v.9.2 (SAS Institute, Cary, North Carolina). 
 
Data sharing  
Anonymized Individual Participant Data (IPD) are already available in VISTA-endovascular, an 
open access registry (http://www.vista.gla.ac.uk)  
 
Role of the funding source 
An unrestricted grant was provided to the University of Calgary by Medtronic who had no role in 
study design, the collection, analysis or interpretation of data, the writing of the report or the deci-
sion to submit the paper for publication. The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to submit for publication. 
 
RESULTS 
We obtained data from the 1764 randomized participants, 871 patients assigned to endovascular 
thrombectomy (intervention population) and 893 assigned to standard medical treatment (control 
population). Pre-randomization brain imaging features were evaluated in 1388 patients on CT and 
in 364 patients on MRI. (Supplementary material Figure S2) Clinical characteristics and imaging 
features at baseline were balanced between the two treatment groups, but treatment with 
intravenous alteplase was more frequent in the control group (Table 1). 
 
Treatment with EVT was associated with reduced disability at 90 days (adjusted common Odds 
Ratio for a shift in direction towards a better functional outcome on the mRS 2·00, 95% CI 1·69–
2·38; p<0·0001). Figure 1 shows the effect of EVT vs. control on mRS at 90 days stratified by pre-
specified baseline imaging features. Distribution of 90-day mRS by treatment group and baseline 
imaging features are shown in Supplement eFigures 3-8. A treatment effect favoring EVT over 
control was observed in a broad range of pre-specified imaging strata. (Figure 1) .The treatment 
effect favored EVT over standard treatment across all three ASPECTS (0-4, 5-7, 8-10) categories 
(interaction p value=0·054). Treatment effects favoring EVT over control were observed in both the 
CT and the MRI sub-groups. (Supplement eFigure 9). In analysis of treatment  effect across each 
individual ASPECTS grade, since point estimates for treatment effect likely favored EVT for each 
individual ASPECTS grades except 0-2, an exploratory analyses informed by potential direction of 
treatment effect across each individual ASPECTS grade was attempted. In this analysis, statistically 
significant treatment effect favoring EVT were seen in patients with baseline ASPECTS 6-10 and 
3-5. The point estimate of treatment effect (common odds ratio) was < 1 in the ASPECTS 0-2 group 
(n=37); however, no statistically significant interaction for treatment effect size was noted across 
the three exploratory ASPECTS categories (6-10, 3-5, 0-2) (interaction p value = 0.30) (Figure 2) 
 
Table 2 summarizes results for secondary outcomes. A beneficial effect of EVT over control was 
seen across all imaging features for most pre-specified secondary outcomes. A statistically 
significant interaction between treatment effect and clot burden score was found for functional 
independence and dramatic neurological recovery at 24 hours (patients with more extensive 
thrombus at baseline likely benefit more with EVT); however, point estimates for treatment effect 
favored EVT across all strata. 
 
In analysis of safety outcomes, no statistically significant difference was noted in 90-day-mortality 
(14·7% vs. 17·3%, p value = 0.15), sICH (3·8% vs. 3·5%, p value = 0.90) and PH2 (5·6% vs. 4·8%, 
p value = 0.52) between EVT and control group.  No treatment effect modification by baseline 
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 8 
imaging features was noted for 90-day-mortality and PH2 (Figure 3 and Supplementary Material 
Figure S9). When considering intracranial hemorrhage, results were inconsistent.  
EVT was associated with a higher risk of sICH in patients with low ASPECTS (0-4) (19·2% versus 
4·5%, adjusted common Odds Ratio 3·94, 95% CI 0·94–16·49, interaction P= 0·025) and in 
patients with baseline early ischemic change in > 1/3 of the MCA territory (13·9% versus 3·5%, 
adjusted common Odds Ratio 4·17, 95% CI 1·3–13·44, interaction P=0·012) but not when the 
outcome was purely radiological using PH2. (Figure 3 and Supplement eFigure 10). No interaction 
was observed with thrombolysis or no thrombolysis in this group of patients. Among patients with 
ASPECTS 0-4, sICH was observed in 10/52 (19·2%) patients in the EVT group vs. 3/56 (4·5%) 
patients in the control group (p value = 0·016). Similarly, sICH was observed in 15/108 (13·9%) 
patients in the EVT group vs.4/113 (3·5%) patients in the control group among patients with 
baseline early ischemic change in > 1/3rd of the MCA territory (p value = 0·007 (Table 3).  
 
DISCUSSION 
Our patient level meta-analysis supports the benefit of EVT for acute ischemic stroke across a broad 
range of imaging sub-groups.  Our results complement and add to previous work from the 
HERMES Collaboration that demonstrated benefit of EVT across a broad range of clinical 
subgroups.
8
 Our analysis is larger than this previous work (7 trials instead of 5, 1764 patients 
instead of 1287), uses more rigorous imaging analysis (HERMES core lab uniform re-reading of all 
scans from all trials), and analyzes key imaging subgroups not previously analyzed. Our results 
suggest that the prevailing opinion of futility associated with EVT in patients with larger infarcts 
identified on baseline imaging may not be appropriate, at least among patients otherwise deemed 
eligible to participate in the component clinical trials of the collaboration. We show benefit with 
EVT over standard care even in patients with low baseline ASPECTS. Our findings are in line with 
recent CT perfusion based studies derived from the same cohort of patients, which were also not 
able to identify baseline ischemic core volumes associated with treatment futility.
25
 
 
EVT is offered to patients with acute ischemic stroke when there is a target artery occlusion and 
what is presumed to be salvageable brain beyond that occlusion, based on interpretation of various 
imaging modalities.
26
 Thrombus in proximal intracranial arterial segments like in the ICA and M1 
MCA are more easily reached by current EVT than thrombus in more distal arterial segments.
10
 
Proximal intracranial arterial segment thrombi are also larger in volume (greater clot burden) than 
more distal thrombi. Unlike EVT therefore, intravenous alteplase is less likely to recanalize 
proximal thrombi early when compared to thrombi in distal arterial segments.
27
 Moreover, patients 
with thrombi in proximal intracranial arterial segments are likely to have greater amount of brain 
tissue at risk than patients with more distal thrombi. . 
 
Imaging is also used to identify extent of irreversibly injured brain tissue beyond target artery 
occlusion. Patients with large extent of irreversibly injured brain are less likely to have brain tissue 
that is salvageable with EVT.
10,14,16
 Both ASPECTS and the 1/3
rd
 MCA rule identify extent of 
probably irreversibly injured brain on CT or MRI.
20,23
 Our analysis suggests relative treatment 
benefit with EVT across all ASPECTS categories and in patients with brain infarcts occupying > 
1/3
rd
 of the ischemic MCA territory. The effect size by ASPECTS categories is however graded, 
with larger effect sizes noted in patients with higher ASPECTS.  Despite evidence of treatment 
benefit, the prognosis for patients with low ASPECTS remains poor with few achieving 
independent outcomes.  We also note a statistically significant benefit with EVT even in patients 
with baseline ASPECTS 3-5, an ASPECTS category that until now may have been considered as 
indicative of treatment futility.
13
 Faster and better reperfusion techniques available since the 
HERMES trials, may magnify potential benefit in these patients from EVT.
28
 The number of 
patients with ASPECTS 0 (n=12), 1 (n=13), 2 (n=12) in our analyses was very few; this is also the 
only imaging sub-group where the point estimate for treatment effect does not favor EVT. Ongoing 
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clinical trials like TENSION and IN EXTRMEIS are likely to provide more evidentiary support for 
or against net benefit of thrombectomy in patients with large ischemic core at baseline. 
 
Patients with good collateral circulation status beyond target arterial occlusion are more likely to 
have salvageable brain than patients with poorer collaterals.
29
 CTA (or MRA) is often used to 
identify patients with poor collateral circulation. The technique therefore complements CT/MRI by 
identifying patients with large extent of irreversibly injured brain tissue. The ESCAPE trial used 
collateral circulation status to exclude patients with poor collaterals; other trials like SWIFT-
PRIME and EXTEND-IA used CT Perfusion or MR Perfusion, techniques that are based on the 
same principle of blood flow imaging that collateral assessments are based on, for selecting patients 
for those trials.
3,4,7
 Like ASPECTS and the 1/3
rd
 MCA rule on CT/MRI, our analyses suggests 
benefit with EVT across all strata of collateral circulation status; however, patients with poor 
collaterals are less likely to benefit with EVT than those with better collaterals. Assessment of poor 
collateral circulation using dynamic angiographic techniques (rather than the single-phase CTA or 
MRA used in a majority of patients in our analyses) may help better identify patients unlikely to 
benefit with EVT.
30
  
 
Finally, imaging is used to determine risk with treatment. Our analyses suggest that sICH rates are 
four times more common in patients with ASPECTS 0-4 and hypodensity in > 1/3
rd
 of the ischemic 
MCA territory. This increase in sICH rates with EVT was not influenced by age, baseline stroke 
severity or intravenous alteplase use. A net beneficial effect of EVT was, however, still seen in 
these patients. 
 
Our study has limitations. Since five out of the seven HERMES trials used baseline imaging criteria 
to exclude patients likely to have large infarcts, we therefore had relatively few patients with such 
imaging signatures in our analyses. Our results are reasonably consistent across both CT and MRI, 
and the sensitivity analyses suggest similar effects but could not confirm a significant benefit of 
thrombectomy in patients with largest baseline infarcts when assessed separately by either CT or 
DWI MRI. Confirmatory randomized trials are in progress. No statistical adjustment for multiple 
comparisons was included. The central re-analysis of images in this study may not reflect the quali-
ty of on-site assessments. In clinical practice, patients are treated based on investigator reads, not 
expert consensus reads. There was heterogeneity in the use of imaging tools, techniques and scan-
ners in our study.
10
 This heterogeneity is however reflective of real world practice. 
 
In summary, in the first individual patient level meta-analysis analyzing the utility of baseline 
imaging in patients eligible for EVT, we found limited evidence of heterogeneity of treatment effect 
across imaging subgroups. Our analysis suggests that estimated treatment effect for EVT should be 
weighted in conjunction with other predictors of outcome when deciding whether or not to offer 
therapy to patients with large baseline infarcts. 
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TABLES 
 
Variables Endovascular group (N=871) Control group (N=893) 
Age in years (Median, Range) 67.4 (23.1, 92.5) 67.8 (18.0, 96.7) 
Female Sex (%) 47.3% (412/871) 47.3% (421/891) 
NIHSS at baseline (Median, Range) [17] (3, 30) [17] (4, 38) 
Onset to randomization in minutes (Median, Range) [181] (49, 713) [184] (37, 708) 
Intravenous alteplase (%) 87.6% (763/871) 90.6% (809/893) 
Baseline ASPECTS (Median, Range) [8] (0, 10) [8] (0, 10) 
Clot burden score (Median, Range) [4] (0, 9) [4.0] (0, 10) 
MCA > 1/3 involvement (%) 13.3% (114/860) 13.6% (119/876) 
Hyperdense vessel sign (%) 51.8% (356/687) 47.1% (330/701) 
Thrombus location (%)     
   ICA 26.3% (215/818) 27.4% (227/828) 
   Proximal M1 MCA 38.5% (315/818) 39.5% (327/828) 
   Distal M1 MCA 27.0% (221/818) 25.4% (210/828) 
   M2 MCA  8.2% (67/818)  7.7% (64/828) 
Collateral circulation grade (%)     
0  0.9% (6/639)  1.2% (8/651) 
1 14.2% (91/639) 16.6% (108/651) 
2 44.3% (283/639) 42.2% (275/651) 
3 40.5% (259/639) 39.9% (260/651) 
NIHSS, National Institute of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early CT Score; ICA, Internal Cerebral Artery; MCA, Middle Cerebral 
Artery. 
Table 1: Baseline clinical and imaging variables by treatment groups. 
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 mRS 0-2 mRS 0-1 Dramatic neurological improvement at 24h* NIHSS 0-2 at 24h 
 
EVT 
(%) 
Control 
(%) OR (95% CI) p-value 
EVT 
(%) 
Control 
(%) OR (95% CI) p-value 
EVT 
(%) 
Control 
(%) OR (95% CI) 
p-
value 
EVT 
(%) 
Control 
(%) 
OR 
(95% CI) p-value 
Imaging Subgroups ( CT OR MR IMAGIG MODALITY) 
All subjects 
[n=1743] 47.8% 30.6% 2.32 (1.87-2.87) NA 29.3% 16.6% 
2.29 (1.74-
3.01) NA 49.5% 23.8% 
3.20 (2.59-
3.96) NA 20.0% 9.3% 
2.91 
(2.13-
3.96) 
 NA 
ASPECTS 0 to 
4 [n=126] 24.6% 14.5% 2.72 (0.89-8.33) 
0.308 
15.8% 5.8% 9.10 (0.96-
86.76) 
0.251 
31.4% 10.8% 4.62 (1.61-
13.25) 
0.516 
2.0% 1.6% 
0.05 
(0.00-
267) 
0.557 ASPECTS 5 to 
7 [n=615] 43.6% 29.4% 2.07 (1.43-2.99) 22.7% 15.9% 
1.61 (1.04-
2.48) 43.8% 19.4% 
3.34 (2.28-
4.88) 13.8% 6.6% 
2.68 
(1.47-
4.91) 
ASPECTS 8 to 
10 [n=975] 53.8% 34.0% 2.56 (1.93-3.40) 35.6% 18.9% 
2.64 (1.89-
3.68) 55.4% 28.7% 
3.19 (2.42-
4.20) 26% 12.0% 
3.06 
(2.12-
4.42) 
ASPECTS 0 to 
2 [n=37] 0.0% 11.5% 0.00 (0.00-5.81) 
0.695 
0.0% 0.0% NA 
0.879 
10.0% 12.5% 
0.63 (0.03-
14.11) 
0.756 
0.0% 0.0% NA 
0.864 
ASPECTS 3 to 
5 [n=186] 30.6% 15.6% 
4.27 (1.62-
11.25) 
16.3% 8.9% 
2.76 (0.86-
8.86) 
28.1% 8.2% 
5.53 (2.06-
14.84) 
6.8% 3.6% 
1.70 
(0.32-
9.15) 
ASPECTS 6 to 
10 [n=1493] 51.0% 33.4% 2.29 (1.83-2.88) 31.6% 18.4% 
2.25 (1.69-
2.99) 
52.7% 26.4% 
3.16 (2.53-
3.95) 
21.8% 10.4% 
2.88 
(2.09-
3.95) 
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MCA 1/3 
involvement no 
[n=1487] 
51.1% 32.9% 2.38 (1.89-2.98) 
0.495 
31.6% 18.3% 2.27 (1.70-
3.03) 
0.962 
52.5% 26.3% 3.13 (2.50-
3.91) 
0.359 
22.2% 10.4% 
2.93 
(2.14-
4.02) 
0.458 
MCA 1/3 
involvement 
yes [n=229] 
27.4% 17.9% 2.23 (1.07-4.65) 15.0% 7.7% 3.16 (1.08-
9.24) 29.1% 9.9% 
4.74 (2.12-
10.62) 3.9% 2.7% 
0.08 
(0.00-
215) 
Hyperdense 
sign no [n=692] 45.7% 30.8% 1.95 (1.39-2.70) 
0.034 
28.0% 13.6% 2.40 (1.65 
(3.50) 
0.997 
48.5% 22.9% 4.59 (1.65-
12.23) 
0.416 
18.6% 8.8% 
2.83 
(1.71-
4.70) 
0.962 
Hyperdense 
sign yes 
[n=682] 
46.6% 23.8% 3.20 (2.26-4.53) 27.7% 14.0% 2.47 (1.70-
3.60) 50.1% 22.3% 
3.67 (2.58-
5.20) 20.9% 9.1% 
3.03 
(1.83-
5.02) 
Clot burden 
score 0 to 4 
[n=1026] 
41.5% 23.4% 2.84 (2.07-3.90) 
0.038 
24.4% 12.1% 2.69 (1.79-
4.05) 
0.244 
47.7% 20.0% 3.61 (2.71-
4.81) 
0.082 
16.9% 6.2% 
4.14 
(2.56-
6.68) 
0.042 Clot burden 
score 5 to 7 
[n=475] 
57.4% 45.4% 1.77 (1.19-2.64) 38.7% 25.8% 1.94 (1.17-
3.19) 52.2% 33.6% 
2.41 (1.59-
3.64) 24.9% 16.5% 
1.82 
(1.11-
2.96) 
Clot burden 
score 8 to 10 
[n=135] 
58.0% 40.9% 2.31 (1.06-5.04) 36.2% 22.7% 2.30 (0.72-
7.30) 47.8% 21.9% 
3.77 (1.64-
8.64) 26.1% 9.4% 
3.70 
(1.21-
11.30) 
ICA [n=440] 33.0% 15.5% 2.91 (1.79-4.73) 0.249 17.8% 8.4% 2.26 (1.23-
4.15) 0.909 42.2% 15.1% 
3.87 (2.41-
6.21) 0.242 9.3% 3.7% 
3.05 
(1.23-
7.60) 
0.416 
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Proximal M1 
[n=631] 47.0% 28.9% 2.63 (1.76-3.93) 27.8% 15.4% 
2.42 (1.43-
4.09) 51.1% 24.6% 
3.18 (2.25-
4.50) 21.9% 8.6% 
3.81 
(2.23-
6.51) 
Distal M1 
[n=428] 58.6% 48.1% 1.67 (1.10-2.54) 40.5% 26.4% 
2.00 (1.16-
3.43) 52.6% 34.6% 
2.29 (1.46-
3.59) 25.2% 17.2% 
1.84 
(1.09-
3.12) 
M2 [n=130] 58.2% 39.7% 2.35 (1.07-5.14) 37.3% 20.6% 2.49 (0.80-
7.75) 47.8% 18.0% 
4.73 (2.00-
11.21) 26.9% 8.2% 
4.38 
(1.39-
13.82) 
Collateral grade 
0 or 1 [n=211] 27.1% 13.9% 1.80 (0.69-4.71) 
0.402 
15.6% 5.2% 4.05 (1.03-
15.91) 
0.623 
31.9% 18.3% 2.18 (1.04-
4.55) 
0.145 
11.2% 2.9% 
3.47 
(0.48-
25.12) 
0.975 Collateral grade 
2 [n=552] 44.0% 28.5% 2.49 (1.68-3.69) 27.7% 14.1% 
2.90 (1.80-
4.69) 47.3% 23.8% 
3.01 (2.07-
4.39) 20.4% 8.8% 
3.92 
(2.20-
6.99) 
Collateral grade 
3 [n=515] 55.4% 33.5% 2.63 (1.80-3.84) 33.3% 17.9% 
2.25 (1.47-
3.45) 56.3% 23.3% 
4.30 (2.89-
6.40) 21.9% 9.5% 
2.95 
(1.71-
5.10) 
*defined as neurological improvement of ≥ 8 points in the NIHSS or a NIHSS 0-1 24 hours after stroke. 
mRS, the modified Rankin Scale; CT, Computed Tomography; MRI, Magnetic Resonance Imaging; CTA, Computed Tomography Angiography; MRA, Magnetic Resonance Angiography; NIHSS, National Institute 
of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early CT Score; ICA, Internal Cerebral Artery; MCA, Middle Cerebral Artery. 
Table 2: Endovascular treatment effect by baseline imaging variable categories on secondary outcomes. 
 
 
 
 
Manuscript reference number: THELANCETNEUROLOGY-D-18-00326R3  
 
 18 
 
 
 
 
 
 
Subgroup 
Endovascular group Control group 
Odds Ratio 
(95% CI) 
p-value 
(subgroup) 
p-value  
(interaction) 
% (n/N) % (n/N) 
Baseline ASPECTS          
   0-4
 
19.2% (10/52)
 
4.5% (3/66)
 
5.00 (1.30,19.25)
 
0.016
 
 
   5-7
 
3.8% (12/319)
 
3.7% (11/297)
 
1.02 (0.44, 2.34)
 
1
 
0.026
 
   8-10
 
2.1% (10/473)
 
3.4% (17/498)
 
0.61 (0.28, 1.35)
 
0.245
 
 
   0-2
 
11.1% (1/9)
 
4.2% (1/24)
 
2.88 (0.16, 51.53)
 
0.477
  
   3-5
 
14.7% (14/95)
 
3.4% (3/87)
 
4.84 (1.27, 27.03)
 
0.010
 
0.008
 
   6-10
 
2.3% (17/740)
 
3.6% (27/750)
 
0.63 (0.32, 1.21)
 
0.168
  
MCA > 1/3 involvement         
   No 2.3% (17/736) 3.6% (27/748) 0.63 (0.34, 1.17) 0.168 0.002
    Yes 13.9% (15/108) 3.5% (4/113) 4.40 (1.41, 13.70) 0.007 
Hyperdense sign         
   No 3.3% (12/360) 3.5% (14/401) 0.95 (0.43, 2.09) 1 0.865
    Yes 4.5% (16/353) 5.2% (17/328) 0.87 (0.43, 1.75) 0.724 
Clot burden score         
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   8-10 0.0% (0/69) 7.5% (5/67) 0.00 (0.00, 0.95) 0.027  
   5-7 4.7% (11/233) 2.9% (7/240) 1.65 (0.63, 4.33) 0.344 
0.063
 
   0-4 3.4% (17/503) 3.1% (16/513) 1.09 (0.54, 2.18) 0.861  
Occlusion location         
   ICA 3.3% (7/210) 2.6% (6/227) 1.27 (0.42, 3.84) 0.781 
0.154
 
   Proximal M1 3.9% (12/307) 3.5% (11/318) 1.14 (0.49, 2.61) 0.834 
   Distal M1 4.1% (9/218) 2.9% (6/207) 1.44 (0.50, 4.13) 0.603 
   M2 0.0% (0/67) 7.8% (5/64) 0.00 (0.00, 0.96) 0.026 
Collateral grade         
3 3.1% (8/259) 2.7% (7/259) 1.15 (0.41, 3.21) 1  
2 3.2% (9/281) 2.9% (8/275) 1.10 (0.42, 2.91) 1 
0.443
 
   0-1 5.3% (5/94) 10.5% (12/114) 0.48 (0.16, 1.41) 0.209  
ASPECTS, Alberta Stroke Program Early CT Score; ICA, Internal Cerebral Artery; MCA, Middle Cerebral Artery. 
Table 3: Symptomatic intracerebral hemorrhage (sICH) rate by treatment and baseline imaging variable 
categories  
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FIGURES 
 
Figure 1. Endovascular treatment effect by baseline imaging variable categories on primary outcome (mRS shift at 90 
days) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASPECTS, Alberta Stroke Program Early CT score; ICA, internal carotid artery; MCA, Middle cerebral artery; M1, M1 
segment of MCA; M2, M2 segment of MCA; mRS, modified Rankin Scale; OR, common Odds Ratio; LCL, lower 
confidence limit;  UCL, upper confidence limit. 
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Figure 2. Panel A shows endovascular treatment effect by individual baseline ASPECTS grades on primary outcome 
(mRS shift at 90 days). There was no statistical evidence of heterogeneity across ASPECTS categories for the 
relationship between treatment and primary outcome. Panel B shows exploratory analysis informed by pre-specified 
analyses of treatment effect by individual baseline ASPECTS grades and combines individual ASPECTS grades into 
categories (6-10 vs. 3-5 and 0-2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASPECTS, Alberta Stroke Program Early CT score; mRS, modified Rankin Scale; OR, common Odds Ratio; LCL, 
lower confidence limit; UCL, upper confidence limit. 
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Figure 3: Endovascular treatment effect by baseline imaging variable categories on safety outcomes, namely, mortality 
at 90 days and symptomatic ICH incidence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASPECTS, Alberta Stroke Program Early CT score; ICA, internal carotid artery; MCA, Middle cerebral artery; M1, M1 
segment of MCA; M2, M2 segment of MCA; mRS, modified Rankin Scale; OR, common Odds Ratio; LCL, lower 
confidence limit;  UCL, upper confidence limit. 
Manuscript reference number: THELANCETNEUROLOGY-D-18-00326R3  
 
 1 
Imaging features and safety and efficacy of endovascular stroke treatment: an individual pa-
tient data meta-analysis  
 
Luis San Roman, MD
1
*, Bijoy K Menon, MD
2
*, Jordi Blasco, MD
1
, María Hernández-Pérez, MD
3
, 
Antoni Davalos, MD
3
, Charles Majoie, MD
4
, Bruce C.V. Campbell, MD
5
, Francis Guillemin, MD
6
, 
Hester Lingsma, PhD
7
, René Anxionnat, MD
8
, Jonathan Epstein, MD
6
, Jeffrey L. Saver, MD
9
, 
Henk Marquering, PhD
10
, John H. Wong, MD
2
, Demetrius Lopes, MD
11
, Gernot Reimann, MHBA 
12
, Hubert Desal, MD
13
, Diederik W.J. Dippel, MD
14
, Shelagh Coutts, MD
2
, Richard du Mesnil de 
Rochemont, MD
15
, Dileep Yavagal, MD
 16
, Jean Christophe Ferre, MD
 17
, Yvo B. W. E. M Roos, 
MD
 18
, David S. Liebeskind, MD
 19
, Robert Lenthall, MD
 20
, Carlos Molina, MD
 21
, Fahad S Al 
Ajlan, MD
 22
, Vivek Reddy, MD
 23
, Dar Dowlatshahi, MD
 23
, Sourour Nader-Antoine, MD
 24
, Cath-
erine Oppenheim, MD
 25
, Alim P Mitha, MD
 2
, Stephen M. Davis, MD
 5
, Christian Weimar, MD 
26
, 
Robert J. van Oostenbrugge, MD
 27
, Erik Cobo, MD
 28
, Timothy J. Kleinig, PhD
 29
, Geoffrey A. 
Donnan, MD
 30
, Aad van der Lugt, MD
 31
, Andrew Demchuk, MD
 2
, Olvert A. Berkhemer, MD
 
14,31,32,38 
, Anna M. M. Boers, MSc
33
, Gary A. Ford, FMedSci 
34
, Keith Muir, MD
 35
, B. Scott 
Brown, PhD
 36
, Tudor Jovin, MD
 37
, Wim H. van Zwam, MD 
38
, Peter J. Mitchell, MD
 39
, Michael 
D Hill, MD
 2
, Phil White, MD
40
, Serge Bracard, MD
41
, Mayank Goyal, MD
2 
on behalf of the 
HERMES collaborators. 
 
LsR and BKM have contributed equally* 
 
1 
Department of Interventional Neuroradiology CDI Hospital Clinic of Barcelona, Spain 
2
Department of Clinical Neurosciences and Radiology, Cumming School of Medicine, University 
of Calgary, Foothills Hospital, Calgary AB, Canada  
3
Department of Neuroscience, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 
Barcelona, Spain 
4
Department of Radiology and Nuclear Medicine, Academic Medical Center, Amsterdam, the 
Netherlands 
5
Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospi-
tal, University of Melbourne, Parkville, Australia 
6
INSERM CIC 1433 Clinical Epidemiology, Université de Lorraine and University Hospital of 
Nancy, Nancy, France 
7
Department of Public Health, Erasmus MC University Medical Center, Rotterdam, the Netherlands 
8
Department of Diagnostic and Interventional Neuroradiology, INSERM U 947, Université de Lor-
raine and University Hospital of Nancy, Nancy, France 
9
Department of Neurology, David Geffen School of Medicine at the University of California, Los 
Angeles, Los Angeles, California, USA  
10
Department of Biomedical Engineering and Physics, Academic Medical Center, the Netherlands 
11
Department of Neurosurgery and Radiology, Rush University Medical Center, Chicago, Illinois  
12
 Stroke-Unit und Neurologische Intensivstation, Klinikum Dortmund gGmbH, Dortmund, 
Germany 
13
Department of Neuroradiology, University and University Hospital of Nantes, France 
14
Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands 
15
Department of Radiology, University Hospital, Frankfurt, Germany 
16
Department of Neurology and Neurosurgery, University of Miami Miller School of Medicine–
Jackson Memorial Hospital, Miami, USA  
17
Department of Neuroradiology, University of Rennes 1 and University Hospital Rennes, France 
18
Department of Neurology, Academic Medical Center, Amsterdam, the Netherlands 
19
Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine at 
the University of California, Los Angeles, Los Angeles, California, USA  
20
Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, UK 
21
 Stroke Unit, Vall d'Hebrón Hospital, Barcelona, Spain 
*Manuscript with revisions highlighted
Manuscript reference number: THELANCETNEUROLOGY-D-18-00326R3  
 
 2 
22
Department of Medicine (Neurology), University of Ottawa, Canada 
23
 Department of Neurology, Drexel University College of Medicine Philadelphia, PA 
23
Department of Medicine (Neurology), University of Ottawa and Ottawa Hospital Research Insti-
tute, Canada 
24 
Department of Neuroradiology. Pitié-Salpêtrière Hospital. APHP. Paris. France 
25
 Department of Neuroradiology, Sainte-Anne Hospital and Paris-Descartes University, INSERM 
U894, Paris, France 
26 
Department of Neurology and stroke unit, University of Essen, Germany 
27
Department of Neurology, Maastricht, the Netherlands  
28
Barcelona-Tech, Barcelona, Spain 
29
 Department of Neurology Royal Adelaide Hospital Adelaide Australia 
30
The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Aus-
tralia 
31
Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center, Rot-
terdam, The Netherlands. 
32
Department of Radiology and Nuclear Medicine, Academic Medical Center, Amsterdam, the 
Netherlands 
33
 Departments of Biomedical Engineering and Physics, Radiology and Nuclear Medicine, Academ-
ic Medical Centre, Amsterdam, the Netherlands 
34
 Consultant Physician, Oxford University Hospitals NHS Foundation Trust, Oxford Science Park, 
Oxford, UK 
35
Institute of Neuroscience & Psychology, University of Glasgow, Queen Elizabeth University 
Hospital, Glasgow, UK 
36
Altair Biostatistics, St Louis Park, Minnesota, USA 
37
Stroke Institute, Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, 
USA 
38
Department of Radiology, Maastricht University Medical Centre, Maastricht, The Netherlands 
39
Department of Radiology, Royal Melbourne Hospital, University of Melbourne, Parkville, Aus-
tralia 
40
Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK  
41
Department of Diagnostic and Interventional Neuroradiology, INSERM U 947, University of Lor-
raine and University Hospital of Nancy, Nancy, France 
Acknowledgements and Funding: 
The study sponsor is the University of Calgary. Major funding is provided through an unrestricted 
grant from Medtronic. The funders of the study had no role in study design, data collection, data 
analysis, data interpretation, or elaboration of the report. All authors had full access to all data in the 
study. The HERMES Steering Committee has responsibility for the decision to submit for 
publication. The corresponding author has final responsibility. 
Correspondence to: 
Mayank Goyal, MD, FRCPC, FAHA 
Seaman Family MR Research Centre,  
Foothills Medical Centre,  
1403 - 29th St. NW, Calgary, AB T2N 2T9, Canada 
Ph: 403 944 3379; Fax: 403 270 7907; mgoyal@ucalgary.ca 
 
Cover title:Imaging features and safety and efficacy of endovascular stroke treatment: an 
individual patient data meta-analysis  
Keywords: acute ischemic stroke, endovascular therapy, imaging, CT, MRI 
Word Count: Abstract 480; Research in context : 290 ;  Manuscript text : 2870 
Figures: 3; Tables:2; Supplementary Material:1 
  
Manuscript reference number: THELANCETNEUROLOGY-D-18-00326R3  
 
 3 
 
SUMMARY  
 
Background  
 
Evidence regarding the utility of imaging studies in selecting patients for endovascular 
thrombectomy (EVT) is limited. We aimed to investigate baseline-imaging features associated with 
efficacy and safety of endovascular thrombectomy (EVT) in acute ischaemic stroke caused by ante-
rior large vessel occlusion. 
 
Methods  
 
The HERMES (Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials) 
Collaboration identified 7 randomized endovascular stroke trials listed in PubMed from 1/Jan/2010 
to 31/October/2017 as comparing EVT to standard medical therapy. Only trials that required vessel 
imaging to identify patients with proximal anterior circulation ischemic stroke and used 
predominantly stent retrievers or second-generation neuro-thrombectomy devices in the EVT arm 
were included. The risk of bias was assessed using the Cochrane tool and was low except in the 
THRACE study that employed un-blinded assessment of 90-day outcome and MRI predominantly 
as the primary baseline imaging tool.  Central, blinded readers rated baseline imaging for ischemic 
change using the Alberta Stroke Program Early Computed Tomography score (ASPECTS) or 
ischemic change involving > 1/3 of middle cerebral artery territory, thrombus volume, 
hyperdensity, and collateral status. Primary endpoint was the modified Rankin Scale (mRS) score at 
90 days. Safety outcomes included symptomatic intracranial hemorrhage (sICH), parenchymal 
hematoma type 2 (PH2) within 5 days of randomization, and mortality within 90 days. 
Primary analysis used mixed methods ordinal logistic regression adjusted for age, sex, NIHSS score 
at admission, intravenous alteplase and time from onset to randomization and interaction terms to 
test if imaging categorization at baseline modifies the relationship between treatment and outcome. 
 
Findings  
Among 1764 pooled patients, 871 were allocated to the EVT arm and 893 to control. The overall 
treatment effect favored EVT (adjusted common Odds Ratio for a shift towards better outcome on 
the mRS 2·00, 95% CI 1·69–2·38; p<0·0001). EVT achieves better 90 day outcomes than medical 
therapy alone across a broad range of baseline imaging categories including in patients with low 
ASPECTS 0-4 (adjusted common Odds Ratio 2·15, 95% CI 1·06–4·37, interaction P= 0·054), > 1/3 
MCA territory infarct (adjusted common Odds Ratio 1·70, 95% CI 1·04–2·78, interaction P= 
0·262), poor collaterals (adjusted common Odds Ratio 1·49, 95% CI 0·86–2·55, interaction P= 
0·296) and all levels of clot burden (interaction P= 0·050). 
No treatment effect modification by baseline imaging features was noted for 90-day-mortality and 
PH2. Higher risk of sICH was seen in patients with ASPECTS 0-4 (19·2% versus 4·5%, adjusted 
common Odds Ratio 3·94, 95% CI 0·94–16·49, interaction P= 0·025) and with > 1/3 MCA territory 
infarct (13·9% versus 3·5%, adjusted common Odds Ratio 4·17, 95% CI 1·3–13·44, interaction 
P=0·012) when allocated EVT. 
 
Interpretation  
EVT achieves better 90-day outcomes than control across a broad range of baseline imaging catego-
ries. This analysis provides evidentiary support to expand existing practice guidelines to provide 
EVT, in a qualified manner, even in patients with large infarcts at baseline.  
 
 
Funding Unrestricted grant from Medtronic. 
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Research in context   
 
Evidence before the study: 
 
Recent randomized trials have demonstrated the efficacy of endovascular thrombectomy (EVT). 
The Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials (HERMES) 
collaboration published in Feb 2016 a pooled analysis of individual patient-level data of the first 
five randomized trials of endovascular thrombectomy. It confirmed benefit of endovascular 
thrombectomy across a wide range of clinical subgroups and reported on the effect of ASPECTS 
and site of vessel occlusion as assessed by each individual trial. However, evidence regarding utility 
of imaging in selecting patients for EVT is limited. 
                                                                                     
 Added value of this study  
 
This is the first individual level meta-analysis using imaging data obtained through single core lab 
analysis from all seven randomized endovascular stroke trials listed in PubMed (1/Jan/2010-
31/October/2017) comparing EVT to standard medical therapy in patients with acute ischemic 
stroke and anterior circulation large vessel occlusion. Trials requiring imaging to identify patients 
with anterior circulation ischemic stroke and using second-generation neuro-thrombectomy devices 
in the EVT arm were included. It represents a unique dataset that is unlikely to ever be replicated in 
the future, as randomized trials of thrombectomy for large vessel occlusion stroke in the patient 
population studied by these trials are no longer considered ethically justifiable. This meta-analysis 
provides new and substantial evidence that patients with a broad range of baseline imaging 
characteristics including those with larger infarcts, poor collaterals and any clot burden score 
benefit from endovascular thrombectomy (EVT).   
     
Implications of all the available evidence 
Current guidelines by the American Heart Association (AHA) recommend EVT in patients with 
ASPECTS>5. This analysis provides evidentiary support for expansion of existing practice guide-
lines to endorse, in a qualified manner, EVT even for patients with large infarcts at baseline (AS-
PECTS as low as 3). 
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INTRODUTION 
Recent randomized clinical trials have established the efficacy and safety of endovascular 
thrombectomy (EVT) in the treatment of patients with acute ischemic stroke and proximal anterior 
circulation occlusion.
1-8
 Because clinical benefit observed in these trials is time dependent, the need 
for fast and efficient patient selection is well recognized.
9
 Imaging is widely used to determine 
prognosis and to select patients for EVT.
10-12
 After the results of the five trials reported in 2015, the 
new AHA guidelines recommend EVT as standard of care (Level I, Class A evidence) in patients 
with baseline non-contrast CT ASPECTS 6-10.
13
 
 
Imaging features are strong predictors of clinical outcome.
10
 Large infarcts at baseline, large 
thrombus in proximal arteries and poor collateral circulation identified using imaging are overall 
associated with lower likelihood of functional dependence and increased risk after reperfusion 
therapies.
14-19
 However, evidence regarding the utility of these imaging features in selecting patients 
for EVT is limited. This patient level meta-analysis of the HERMES (Highly Effective Reperfusion 
evaluated in Multiple Endovascular Stroke Trials) Collaboration aims to determine baseline-
imaging features associated with efficacy and safety of EVT when compared to standard medical 
therapy.  
 
 
METHODS 
Study design and participants  
We searched Pubmed for randomized trials published between 1 Jan 2010 and 31 October 2017 
comparing endovascular thrombectomy performed using predominantly stent-retrievers with stand-
ard care in anterior circulation ischaemic stroke patients - Pubmed search string: (("randomized 
controlled trial"[Publication Type]) AND ((thrombectomy [Title/Abstract]) OR (clot retrieval [Ti-
tle/Abstract]) OR intraarterial[Title/Abstract]) AND (stroke[Title/Abstract]) AND 
("2010/01/01"[Date - Publication] : "2017/10/31"[Date - Publication])). 
The HERMES (Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials) 
Collaboration pooled patient level demographic, clinical and imaging data as well as functional and 
radiologic outcomes from 7 randomized trials: MR CLEAN, ESCAPE, EXTEND-IA, SWIFT 
PRIME, REVASCAT, THRACE and PISTE  (Supplement eFigure 1). All these trials required ves-
sel imaging to identify patients with anterior circulation ischemic stroke and used predominantly 
stent retrievers or second-generation neuro-thrombectomy devices in the EVT arm. Data were as-
sessed for quality and validity using PRISMA guidelines. Differences in patient population, sam-
pling frame and operational definitions of intervention (EVT) and control were assessed before col-
lating all data at a patient level (Supplement eTable 1). Risk of bias in the individual studies was 
assessed using the Cochrane handbook methodology and was low overall except in the THRACE 
study that used un-blinded assessment of 90-day outcome. In addition, in contrast to other studies, 
the THRACE study used MRI predominantly as the primary baseline imaging tool. This meta-
analysis was prospectively designed by the HERMES executive committee but not registered. All 
participants provided informed consent according to each trial protocol and each study was ap-
proved by the local ethics board. The methodological design for this patient level pooling has been 
previously described.
8
  
Imaging variables 
Baseline images included information available either on Computed Tomography (CT) or on 
Magnetic Resonance Imaging (MRI). All imaging studies were de-identified at the HERMES 
central coordinating center. The imaging datasets were then read by independent HERMES core 
labs for baseline CT/MRI, baseline CT Angiography (CTA), MRI Angiography (MRA), follow up 
CT or MR, and conventional angiography. Readers were blinded to all clinical information, except 
side of stroke.  
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Imaging in acute ischemic stroke is used to identify extent of early ischemic change and location 
and extent of thrombus. Pre-specified baseline imaging features of interest therefore were:  
1. The Alberta Stroke Program Early CT Score (ASPECTS) defined on CT or MR Diffusion 
Weighted Imaging (MR-DWI). This widely used ordinal scale measures extent of ischemia 
in the middle cerebral artery (MCA) territory (from score 0 in complete infarction to 10 for 
no infarction) .20 An ASPECTS region was considered as involved on DWI if the lesion 
occupied > 30% of the respective region, and on CT if any signs of ischemia were visible on 
at least two consecutive cuts of the 10 standardized regions of the MCA territory. ASPECTS 
grading was evaluated independently by experts blinded to all clinical and imaging 
information except stroke side. Any disagreement was resolved by consensus. 
Trichotomized ASPECTS agreement between two raters (JB, LSR) assessed in 30 patients 
using weighted kappa was good (kappa 0.89, 95% CI 0.81 -0.99. 
2. The > 1/3rd MCA rule defined on CT or MR-DWI as early ischemic change in > 1/3rd of the 
ischemic MCA territory.
21
 
3. Thrombus location identified on CTA or MRA. Thrombus location was classified as that in 
the intracranial internal carotid artery (ICA), proximal M1 middle cerebral artery (MCA) 
segment, distal M1 MCA segment and M2 MCA segment. Tandem occlusion was defined as 
thrombus in extracranial ICA along with intracranial (ICA, M1-MCA, M2-MCA) 
thrombus.
22 
4. Collateral circulation distal to intracranial thrombus. Collateral circulation was evaluated on 
multi-phase CTA, single phase CTA or contrast-enhanced MRA and classified according to 
a previously published pre-specified collateral grade category (grade 0-1, poor; grade 2, 
intermediate; grade 3, good).
19 
5. Thrombus density on imaging identified using assessment of the hyperdense artery sign on 
CT 23 and thrombus volume on CTA, analyzed using the clot burden score (CBS).
24 
Data on number of patients assessed for each imaging variable at baseline and reasons for exclusion 
are described in Supplement eTable 2. Patients were excluded from further analyses if images were 
unavailable from primary trial or were of poor quality. 
 
Outcomes 
The primary endpoint was neurological functional disability scored on the modified Rankin Scale 
(mRS) 90 days after randomization with categories 5 (severe disability) and 6 (death) collapsed into 
a single category. Secondary efficacy outcomes were functional independence (mRS 0–2) at 90 
days, excellent functional outcome (mRS 0–1) at 90 days and dramatic neurological improvement 
(defined as neurological improvement of ≥ 8 points in the NIHSS or a NIHSS 0-1 24 hours after 
stroke). Safety outcomes included intracranial hemorrhage defined as both symptomatic intracranial 
hemorrhage (sICH; defined by each trial), parenchymal hematoma type 2 (PH2; blood clot 
occupying >30% of the infarcted territory with substantial mass effect) within 5 days of 
randomization, and mortality within 90 days. 
 
Statistical analysis 
All analyses were based on the “as randomized” population. Unless otherwise stated, all reported 
analyses were pre-specified in the Statistical Analysis Plan. (Supplementary Material) To account 
for between trial differences when pooling patient level data, mixed-effects modeling was used for 
all analyses, with fixed effects for parameters of interest and “trial” and the interaction term 
“trial*treatment” as random effects variables in all models.8 Ordinal logistic regression models 
included fixed effects (age, sex, NIHSS score at admission, intravenous alteplase use and time from 
onset to randomization) and multiplicative interaction terms to test if pre-specified baseline-imaging 
features modified the effect of treatment allocation on pre-defined outcomes.  ASPECTS scores 
were trichotomized as 0-4, 5-7 and 8-10 for primary analysis.  In addition, as pre-specified in the 
Statistical Analysis Plan, an attempt was made to analyze treatment effect across each ASPECTS 
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grade to identify an ASPECTS grade below which endovascular treatment may be considered futile 
or potentially harmful.
13
 Sensitivity analyses were performed according to the primary imaging 
modality (CT or MRI) used at baseline. When missing (n= 21), the primary outcome was imputed 
as per methods pre-specified in each of the trials. All statistical analyses were performed using SAS 
v.9.2 (SAS Institute, Cary, North Carolina). 
 
Data sharing  
Anonymized Individual Participant Data (IPD) are already available in VISTA-endovascular, an 
open access registry (http://www.vista.gla.ac.uk)  
 
Role of the funding source 
An unrestricted grant was provided to the University of Calgary by Medtronic who had no role in 
study design, the collection, analysis or interpretation of data, the writing of the report or the deci-
sion to submit the paper for publication. The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to submit for publication. 
 
RESULTS 
We obtained data from the 1764 randomized participants, 871 patients assigned to endovascular 
thrombectomy (intervention population) and 893 assigned to standard medical treatment (control 
population). Pre-randomization brain imaging features were evaluated in 1388 patients on CT and 
in 364 patients on MRI. (Supplementary material Figure S2) Clinical characteristics and imaging 
features at baseline were balanced between the two treatment groups, but treatment with 
intravenous alteplase was more frequent in the control group (Table 1). 
 
Treatment with EVT was associated with reduced disability at 90 days (adjusted common Odds 
Ratio for a shift in direction towards a better functional outcome on the mRS 2·00, 95% CI 1·69–
2·38; p<0·0001). Figure 1 shows the effect of EVT vs. control on mRS at 90 days stratified by pre-
specified baseline imaging features. Distribution of 90-day mRS by treatment group and baseline 
imaging features are shown in Supplement eFigures 3-8. A treatment effect favoring EVT over 
control was observed in a broad range of pre-specified imaging strata. (Figure 1) .The treatment 
effect favored EVT over standard treatment across all three ASPECTS (0-4, 5-7, 8-10) categories 
(interaction p value=0·054). Treatment effects favoring EVT over control were observed in both the 
CT and the MRI sub-groups. (Supplement eFigure 9). In analysis of treatment  effect across each 
individual ASPECTS grade, since point estimates for treatment effect likely favored EVT for each 
individual ASPECTS grades except 0-2, an exploratory analyses informed by potential direction of 
treatment effect across each individual ASPECTS grade was attempted. In this analysis, statistically 
significant treatment effect favoring EVT were seen in patients with baseline ASPECTS 6-10 and 
3-5. The point estimate of treatment effect (common odds ratio) was < 1 in the ASPECTS 0-2 group 
(n=37); however, no statistically significant interaction for treatment effect size was noted across 
the three exploratory ASPECTS categories (6-10, 3-5, 0-2) (interaction p value = 0.30) (Figure 2) 
 
Table 2 summarizes results for secondary outcomes. A beneficial effect of EVT over control was 
seen across all imaging features for most pre-specified secondary outcomes. A statistically 
significant interaction between treatment effect and clot burden score was found for functional 
independence and dramatic neurological recovery at 24 hours (patients with more extensive 
thrombus at baseline likely benefit more with EVT); however, point estimates for treatment effect 
favored EVT across all strata. 
 
In analysis of safety outcomes, no statistically significant difference was noted in 90-day-mortality 
(14·7% vs. 17·3%, p value = 0.15), sICH (3·8% vs. 3·5%, p value = 0.90) and PH2 (5·6% vs. 4·8%, 
p value = 0.52) between EVT and control group.  No treatment effect modification by baseline 
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imaging features was noted for 90-day-mortality and PH2 (Figure 3 and Supplementary Material 
Figure S9). When considering intracranial hemorrhage, results were inconsistent.  
EVT was associated with a higher risk of sICH in patients with low ASPECTS (0-4) (19·2% versus 
4·5%, adjusted common Odds Ratio 3·94, 95% CI 0·94–16·49, interaction P= 0·025) and in 
patients with baseline early ischemic change in > 1/3 of the MCA territory (13·9% versus 3·5%, 
adjusted common Odds Ratio 4·17, 95% CI 1·3–13·44, interaction P=0·012) but not when the 
outcome was purely radiological using PH2. (Figure 3 and Supplement eFigure 10). No interaction 
was observed with thrombolysis or no thrombolysis in this group of patients. Among patients with 
ASPECTS 0-4, sICH was observed in 10/52 (19·2%) patients in the EVT group vs. 3/56 (4·5%) 
patients in the control group (p value = 0·016). Similarly, sICH was observed in 15/108 (13·9%) 
patients in the EVT group vs.4/113 (3·5%) patients in the control group among patients with 
baseline early ischemic change in > 1/3rd of the MCA territory (p value = 0·007 (Table 3).  
 
DISCUSSION 
Our patient level meta-analysis supports the benefit of EVT for acute ischemic stroke across a broad 
range of imaging sub-groups.  Our results complement and add to previous work from the 
HERMES Collaboration that demonstrated benefit of EVT across a broad range of clinical 
subgroups.
8
 Our analysis is larger than this previous work (7 trials instead of 5, 1764 patients 
instead of 1287), uses more rigorous imaging analysis (HERMES core lab uniform re-reading of all 
scans from all trials), and analyzes key imaging subgroups not previously analyzed. Our results 
suggest that the prevailing opinion of futility associated with EVT in patients with larger infarcts 
identified on baseline imaging may not be appropriate, at least among patients otherwise deemed 
eligible to participate in the component clinical trials of the collaboration. We show benefit with 
EVT over standard care even in patients with low baseline ASPECTS. Our findings are in line with 
recent CT perfusion based studies derived from the same cohort of patients, which were also not 
able to identify baseline ischemic core volumes associated with treatment futility.
25
 
 
EVT is offered to patients with acute ischemic stroke when there is a target artery occlusion and 
what is presumed to be salvageable brain beyond that occlusion, based on interpretation of various 
imaging modalities.
26
 Thrombus in proximal intracranial arterial segments like in the ICA and M1 
MCA are more easily reached by current EVT than thrombus in more distal arterial segments.
10
 
Proximal intracranial arterial segment thrombi are also larger in volume (greater clot burden) than 
more distal thrombi. Unlike EVT therefore, intravenous alteplase is less likely to recanalize 
proximal thrombi early when compared to thrombi in distal arterial segments.
27
 Moreover, patients 
with thrombi in proximal intracranial arterial segments are likely to have greater amount of brain 
tissue at risk than patients with more distal thrombi. . 
 
Imaging is also used to identify extent of irreversibly injured brain tissue beyond target artery 
occlusion. Patients with large extent of irreversibly injured brain are less likely to have brain tissue 
that is salvageable with EVT.
10,14,16
 Both ASPECTS and the 1/3
rd
 MCA rule identify extent of 
probably irreversibly injured brain on CT or MRI.
20,23
 Our analysis suggests relative treatment 
benefit with EVT across all ASPECTS categories and in patients with brain infarcts occupying > 
1/3
rd
 of the ischemic MCA territory. The effect size by ASPECTS categories is however graded, 
with larger effect sizes noted in patients with higher ASPECTS.  Despite evidence of treatment 
benefit, the prognosis for patients with low ASPECTS remains poor with few achieving 
independent outcomes.  We also note a statistically significant benefit with EVT even in patients 
with baseline ASPECTS 3-5, an ASPECTS category that until now may have been considered as 
indicative of treatment futility.
13
 Faster and better reperfusion techniques available since the 
HERMES trials, may magnify potential benefit in these patients from EVT.
28
 The number of 
patients with ASPECTS 0 (n=12), 1 (n=13), 2 (n=12) in our analyses was very few; this is also the 
only imaging sub-group where the point estimate for treatment effect does not favor EVT. Ongoing 
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clinical trials like TENSION and IN EXTRMEIS are likely to provide more evidentiary support for 
or against net benefit of thrombectomy in patients with large ischemic core at baseline. 
 
Patients with good collateral circulation status beyond target arterial occlusion are more likely to 
have salvageable brain than patients with poorer collaterals.
29
 CTA (or MRA) is often used to 
identify patients with poor collateral circulation. The technique therefore complements CT/MRI by 
identifying patients with large extent of irreversibly injured brain tissue. The ESCAPE trial used 
collateral circulation status to exclude patients with poor collaterals; other trials like SWIFT-
PRIME and EXTEND-IA used CT Perfusion or MR Perfusion, techniques that are based on the 
same principle of blood flow imaging that collateral assessments are based on, for selecting patients 
for those trials.
3,4,7
 Like ASPECTS and the 1/3
rd
 MCA rule on CT/MRI, our analyses suggests 
benefit with EVT across all strata of collateral circulation status; however, patients with poor 
collaterals are less likely to benefit with EVT than those with better collaterals. Assessment of poor 
collateral circulation using dynamic angiographic techniques (rather than the single-phase CTA or 
MRA used in a majority of patients in our analyses) may help better identify patients unlikely to 
benefit with EVT.
30
  
 
Finally, imaging is used to determine risk with treatment. Our analyses suggest that sICH rates are 
four times more common in patients with ASPECTS 0-4 and hypodensity in > 1/3
rd
 of the ischemic 
MCA territory. This increase in sICH rates with EVT was not influenced by age, baseline stroke 
severity or intravenous alteplase use. A net beneficial effect of EVT was, however, still seen in 
these patients. 
 
Our study has limitations. Since five out of the seven HERMES trials used baseline imaging criteria 
to exclude patients likely to have large infarcts, we therefore had relatively few patients with such 
imaging signatures in our analyses. Our results are reasonably consistent across both CT and MRI, 
and the sensitivity analyses suggest similar effects but could not confirm a significant benefit of 
thrombectomy in patients with largest baseline infarcts when assessed separately by either CT or 
DWI MRI. Confirmatory randomized trials are in progress. No statistical adjustment for multiple 
comparisons was included. The central re-analysis of images in this study may not reflect the quali-
ty of on-site assessments. In clinical practice, patients are treated based on investigator reads, not 
expert consensus reads. There was heterogeneity in the use of imaging tools, techniques and scan-
ners in our study.
10
 This heterogeneity is however reflective of real world practice. 
 
In summary, in the first individual patient level meta-analysis analyzing the utility of baseline 
imaging in patients eligible for EVT, we found limited evidence of heterogeneity of treatment effect 
across imaging subgroups. Our analysis suggests that estimated treatment effect for EVT should be 
weighted in conjunction with other predictors of outcome when deciding whether or not to offer 
therapy to patients with large baseline infarcts. 
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TABLES 
 
Variables Endovascular group (N=871) Control group (N=893) 
Age in years (Median, Range) 67.4 (23.1, 92.5) 67.8 (18.0, 96.7) 
Female Sex (%) 47.3% (412/871) 47.3% (421/891) 
NIHSS at baseline (Median, Range) [17] (3, 30) [17] (4, 38) 
Onset to randomization in minutes (Median, Range) [181] (49, 713) [184] (37, 708) 
Intravenous alteplase (%) 87.6% (763/871) 90.6% (809/893) 
Baseline ASPECTS (Median, Range) [8] (0, 10) [8] (0, 10) 
Clot burden score (Median, Range) [4] (0, 9) [4.0] (0, 10) 
MCA > 1/3 involvement (%) 13.3% (114/860) 13.6% (119/876) 
Hyperdense vessel sign (%) 51.8% (356/687) 47.1% (330/701) 
Thrombus location (%)     
   ICA 26.3% (215/818) 27.4% (227/828) 
   Proximal M1 MCA 38.5% (315/818) 39.5% (327/828) 
   Distal M1 MCA 27.0% (221/818) 25.4% (210/828) 
   M2 MCA  8.2% (67/818)  7.7% (64/828) 
Collateral circulation grade (%)     
0  0.9% (6/639)  1.2% (8/651) 
1 14.2% (91/639) 16.6% (108/651) 
2 44.3% (283/639) 42.2% (275/651) 
3 40.5% (259/639) 39.9% (260/651) 
NIHSS, National Institute of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early CT Score; ICA, Internal Cerebral Artery; MCA, Middle Cerebral 
Artery. 
Table 1: Baseline clinical and imaging variables by treatment groups. 
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 mRS 0-2 mRS 0-1 Dramatic neurological improvement at 24h* NIHSS 0-2 at 24h 
 
EVT 
(%) 
Control 
(%) OR (95% CI) p-value 
EVT 
(%) 
Control 
(%) OR (95% CI) p-value 
EVT 
(%) 
Control 
(%) OR (95% CI) 
p-
value 
EVT 
(%) 
Control 
(%) 
OR 
(95% CI) p-value 
Imaging Subgroups ( CT OR MR IMAGIG MODALITY) 
All subjects 
[n=1743] 47.8% 30.6% 2.32 (1.87-2.87) NA 29.3% 16.6% 
2.29 (1.74-
3.01) NA 49.5% 23.8% 
3.20 (2.59-
3.96) NA 20.0% 9.3% 
2.91 
(2.13-
3.96) 
 NA 
ASPECTS 0 to 
4 [n=126] 24.6% 14.5% 2.72 (0.89-8.33) 
0.308 
15.8% 5.8% 9.10 (0.96-
86.76) 
0.251 
31.4% 10.8% 4.62 (1.61-
13.25) 
0.516 
2.0% 1.6% 
0.05 
(0.00-
267) 
0.557 ASPECTS 5 to 
7 [n=615] 43.6% 29.4% 2.07 (1.43-2.99) 22.7% 15.9% 
1.61 (1.04-
2.48) 43.8% 19.4% 
3.34 (2.28-
4.88) 13.8% 6.6% 
2.68 
(1.47-
4.91) 
ASPECTS 8 to 
10 [n=975] 53.8% 34.0% 2.56 (1.93-3.40) 35.6% 18.9% 
2.64 (1.89-
3.68) 55.4% 28.7% 
3.19 (2.42-
4.20) 26% 12.0% 
3.06 
(2.12-
4.42) 
ASPECTS 0 to 
2 [n=37] 0.0% 11.5% 0.00 (0.00-5.81) 
0.695 
0.0% 0.0% NA 
0.879 
10.0% 12.5% 
0.63 (0.03-
14.11) 
0.756 
0.0% 0.0% NA 
0.864 
ASPECTS 3 to 
5 [n=186] 30.6% 15.6% 
4.27 (1.62-
11.25) 
16.3% 8.9% 
2.76 (0.86-
8.86) 
28.1% 8.2% 
5.53 (2.06-
14.84) 
6.8% 3.6% 
1.70 
(0.32-
9.15) 
ASPECTS 6 to 
10 [n=1493] 51.0% 33.4% 2.29 (1.83-2.88) 31.6% 18.4% 
2.25 (1.69-
2.99) 
52.7% 26.4% 
3.16 (2.53-
3.95) 
21.8% 10.4% 
2.88 
(2.09-
3.95) 
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MCA 1/3 
involvement no 
[n=1487] 
51.1% 32.9% 2.38 (1.89-2.98) 
0.495 
31.6% 18.3% 2.27 (1.70-
3.03) 
0.962 
52.5% 26.3% 3.13 (2.50-
3.91) 
0.359 
22.2% 10.4% 
2.93 
(2.14-
4.02) 
0.458 
MCA 1/3 
involvement 
yes [n=229] 
27.4% 17.9% 2.23 (1.07-4.65) 15.0% 7.7% 3.16 (1.08-
9.24) 29.1% 9.9% 
4.74 (2.12-
10.62) 3.9% 2.7% 
0.08 
(0.00-
215) 
Hyperdense 
sign no [n=692] 45.7% 30.8% 1.95 (1.39-2.70) 
0.034 
28.0% 13.6% 2.40 (1.65 
(3.50) 
0.997 
48.5% 22.9% 4.59 (1.65-
12.23) 
0.416 
18.6% 8.8% 
2.83 
(1.71-
4.70) 
0.962 
Hyperdense 
sign yes 
[n=682] 
46.6% 23.8% 3.20 (2.26-4.53) 27.7% 14.0% 2.47 (1.70-
3.60) 50.1% 22.3% 
3.67 (2.58-
5.20) 20.9% 9.1% 
3.03 
(1.83-
5.02) 
Clot burden 
score 0 to 4 
[n=1026] 
41.5% 23.4% 2.84 (2.07-3.90) 
0.038 
24.4% 12.1% 2.69 (1.79-
4.05) 
0.244 
47.7% 20.0% 3.61 (2.71-
4.81) 
0.082 
16.9% 6.2% 
4.14 
(2.56-
6.68) 
0.042 Clot burden 
score 5 to 7 
[n=475] 
57.4% 45.4% 1.77 (1.19-2.64) 38.7% 25.8% 1.94 (1.17-
3.19) 52.2% 33.6% 
2.41 (1.59-
3.64) 24.9% 16.5% 
1.82 
(1.11-
2.96) 
Clot burden 
score 8 to 10 
[n=135] 
58.0% 40.9% 2.31 (1.06-5.04) 36.2% 22.7% 2.30 (0.72-
7.30) 47.8% 21.9% 
3.77 (1.64-
8.64) 26.1% 9.4% 
3.70 
(1.21-
11.30) 
ICA [n=440] 33.0% 15.5% 2.91 (1.79-4.73) 0.249 17.8% 8.4% 2.26 (1.23-
4.15) 0.909 42.2% 15.1% 
3.87 (2.41-
6.21) 0.242 9.3% 3.7% 
3.05 
(1.23-
7.60) 
0.416 
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Proximal M1 
[n=631] 47.0% 28.9% 2.63 (1.76-3.93) 27.8% 15.4% 
2.42 (1.43-
4.09) 51.1% 24.6% 
3.18 (2.25-
4.50) 21.9% 8.6% 
3.81 
(2.23-
6.51) 
Distal M1 
[n=428] 58.6% 48.1% 1.67 (1.10-2.54) 40.5% 26.4% 
2.00 (1.16-
3.43) 52.6% 34.6% 
2.29 (1.46-
3.59) 25.2% 17.2% 
1.84 
(1.09-
3.12) 
M2 [n=130] 58.2% 39.7% 2.35 (1.07-5.14) 37.3% 20.6% 2.49 (0.80-
7.75) 47.8% 18.0% 
4.73 (2.00-
11.21) 26.9% 8.2% 
4.38 
(1.39-
13.82) 
Collateral grade 
0 or 1 [n=211] 27.1% 13.9% 1.80 (0.69-4.71) 
0.402 
15.6% 5.2% 4.05 (1.03-
15.91) 
0.623 
31.9% 18.3% 2.18 (1.04-
4.55) 
0.145 
11.2% 2.9% 
3.47 
(0.48-
25.12) 
0.975 Collateral grade 
2 [n=552] 44.0% 28.5% 2.49 (1.68-3.69) 27.7% 14.1% 
2.90 (1.80-
4.69) 47.3% 23.8% 
3.01 (2.07-
4.39) 20.4% 8.8% 
3.92 
(2.20-
6.99) 
Collateral grade 
3 [n=515] 55.4% 33.5% 2.63 (1.80-3.84) 33.3% 17.9% 
2.25 (1.47-
3.45) 56.3% 23.3% 
4.30 (2.89-
6.40) 21.9% 9.5% 
2.95 
(1.71-
5.10) 
*defined as neurological improvement of ≥ 8 points in the NIHSS or a NIHSS 0-1 24 hours after stroke. 
mRS, the modified Rankin Scale; CT, Computed Tomography; MRI, Magnetic Resonance Imaging; CTA, Computed Tomography Angiography; MRA, Magnetic Resonance Angiography; NIHSS, National Institute 
of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early CT Score; ICA, Internal Cerebral Artery; MCA, Middle Cerebral Artery. 
Table 2: Endovascular treatment effect by baseline imaging variable categories on secondary outcomes. 
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Subgroup 
Endovascular group Control group 
Odds Ratio 
(95% CI) 
p-value 
(subgroup) 
p-value  
(interaction) 
% (n/N) % (n/N) 
Baseline ASPECTS          
   0-4
 
19.2% (10/52)
 
4.5% (3/66)
 
5.00 (1.30,19.25)
 
0.016
 
 
   5-7
 
3.8% (12/319)
 
3.7% (11/297)
 
1.02 (0.44, 2.34)
 
1
 
0.026
 
   8-10
 
2.1% (10/473)
 
3.4% (17/498)
 
0.61 (0.28, 1.35)
 
0.245
 
 
   0-2
 
11.1% (1/9)
 
4.2% (1/24)
 
2.88 (0.16, 51.53)
 
0.477
  
   3-5
 
14.7% (14/95)
 
3.4% (3/87)
 
4.84 (1.27, 27.03)
 
0.010
 
0.008
 
   6-10
 
2.3% (17/740)
 
3.6% (27/750)
 
0.63 (0.32, 1.21)
 
0.168
  
MCA > 1/3 involvement         
   No 2.3% (17/736) 3.6% (27/748) 0.63 (0.34, 1.17) 0.168 0.002
    Yes 13.9% (15/108) 3.5% (4/113) 4.40 (1.41, 13.70) 0.007 
Hyperdense sign         
   No 3.3% (12/360) 3.5% (14/401) 0.95 (0.43, 2.09) 1 0.865
    Yes 4.5% (16/353) 5.2% (17/328) 0.87 (0.43, 1.75) 0.724 
Clot burden score         
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   8-10 0.0% (0/69) 7.5% (5/67) 0.00 (0.00, 0.95) 0.027  
   5-7 4.7% (11/233) 2.9% (7/240) 1.65 (0.63, 4.33) 0.344 
0.063
 
   0-4 3.4% (17/503) 3.1% (16/513) 1.09 (0.54, 2.18) 0.861  
Occlusion location         
   ICA 3.3% (7/210) 2.6% (6/227) 1.27 (0.42, 3.84) 0.781 
0.154
 
   Proximal M1 3.9% (12/307) 3.5% (11/318) 1.14 (0.49, 2.61) 0.834 
   Distal M1 4.1% (9/218) 2.9% (6/207) 1.44 (0.50, 4.13) 0.603 
   M2 0.0% (0/67) 7.8% (5/64) 0.00 (0.00, 0.96) 0.026 
Collateral grade         
3 3.1% (8/259) 2.7% (7/259) 1.15 (0.41, 3.21) 1  
2 3.2% (9/281) 2.9% (8/275) 1.10 (0.42, 2.91) 1 
0.443
 
   0-1 5.3% (5/94) 10.5% (12/114) 0.48 (0.16, 1.41) 0.209  
ASPECTS, Alberta Stroke Program Early CT Score; ICA, Internal Cerebral Artery; MCA, Middle Cerebral Artery. 
Table 3: Symptomatic intracerebral hemorrhage (sICH) rate by treatment and baseline imaging variable 
categories  
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FIGURES 
 
Figure 1. Endovascular treatment effect by baseline imaging variable categories on primary outcome (mRS shift at 90 
days) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASPECTS, Alberta Stroke Program Early CT score; ICA, internal carotid artery; MCA, Middle cerebral artery; M1, M1 
segment of MCA; M2, M2 segment of MCA; mRS, modified Rankin Scale; OR, common Odds Ratio; LCL, lower 
confidence limit;  UCL, upper confidence limit. 
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Figure 2. Panel A shows endovascular treatment effect by individual baseline ASPECTS grades on primary outcome 
(mRS shift at 90 days). There was no statistical evidence of heterogeneity across ASPECTS categories for the 
relationship between treatment and primary outcome. Panel B shows exploratory analysis informed by pre-specified 
analyses of treatment effect by individual baseline ASPECTS grades and combines individual ASPECTS grades into 
categories (6-10 vs. 3-5 and 0-2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASPECTS, Alberta Stroke Program Early CT score; mRS, modified Rankin Scale; OR, common Odds Ratio; LCL, 
lower confidence limit; UCL, upper confidence limit. 
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Figure 3: Endovascular treatment effect by baseline imaging variable categories on safety outcomes, namely, mortality 
at 90 days and symptomatic ICH incidence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASPECTS, Alberta Stroke Program Early CT score; ICA, internal carotid artery; MCA, Middle cerebral artery; M1, M1 
segment of MCA; M2, M2 segment of MCA; mRS, modified Rankin Scale; OR, common Odds Ratio; LCL, lower 
confidence limit;  UCL, upper confidence limit. 
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SUPPLEMENTARY MATERIAL 
 
Imaging predictors of treatment effects and clinical outcome in acute large vessel stroke: me-
ta-analysis of the Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke 
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II. FIGURES 
 
 
eFigure 1: PRISMA IPD flow diagram illustrating study selection. 
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eFigure 2:  Flow chart describing number of patients assessed for imaging variable at baseline and rea-
sons for exclusion. Missing patients were not included in the  different analysis of each imaging variable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
 
eFigure 3: Distribution of modified Rankin Scale at 90 days stratified by ASPECTS categories in the 
endovascular and control groups (numbers within the horizontal bars represent percentages). 
 
 
 
 
 
 
 
eFigure 4:  Distribution of modified Rankin Scale at 90 days stratified by thrombus location in the endo-
vascular and control groups (numbers within the horizontal bars represent percentages). 
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eFigure 5:  Distribution of modified Rankin Scale at 90 days stratified by collateral circulation score 
categories in the endovascular and control groups (numbers within the horizontal bars represent percent-
ages). 
 
 
 
 
 
eFigure 6:  Distribution of modified Rankin Scale at 90 days stratified by presence or absence of 
hyperdense sign on CT in the endovascular and control groups (numbers within the horizontal bars repre-
sent percentages). 
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eFigure 7:  Distribution of modified Rankin Scale at 90 days stratified by presence or absence of early 
ischemic changes in 1/3rd of MCA territory in the endovascular and control groups (numbers within the 
horizontal bars represent percentages). 
 
 
 
 
eFigure 8:  Distribution of modified Rankin Scale at 90 days stratified by clot burden score categories in 
the endovascular and control groups (numbers within the horizontal bars represent percentages). 
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eFigure 9: Endovascular treatment effect by baseline imaging variable categories on primary outcome 
(mRS at 90 days) stratified by imaging modality (CT vs. MRI). Treatment effect is assessed through the 
common odds ratio for mRS shift. 
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eFigure 10: Endovascular treatment effect by baseline imaging variable categories on imaging safety 
outcome, namely, Parenchymal Hemorrhage Type 2. Treatment effect is assessed through the common 
odds ratio for mRS shift. 
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I. TABLES 
 
eTable 1: Qualitative assessment of between-trial differences in population, sampling frame and opera-
tional definitions of treatment groups. 
 
 
 MR CLEAN ESCAPE EXTEND IA 
SWIFT 
PRIME REVASCAT THRACE PISTE 
Population 
Continent Europe 
North America, 
Europe, East 
Asia Oceania 
North America 
and Europe Europe Europe Europe 
Country Netherlands Multiple 
Australia and 
New Zealand Multiple Spain France 
United King-
dom 
Sampling Frame 
Imaging Criteria 
Modality NCCT/CTA 
NCCT/CTA 
*CTP optional 
NCCT/CTA/CT
P *MRI option-
al 
NCCT/CTA/CT
P *MRI option-
al 
NCCT/CTA 
*CTP optional 
MRI or 
NCCT/CTA NCCT/CTA  
Occlusion Site ICA M1 M2 ICA M1 ICA M1 M2 ICA M1 ICA M1 ICA M1 ICA M1 
Ischaemic 
Core Defini-
tion Not used 
ASPECTS 6-10 
Good Collat-
erals 
CTP mismatch 
and ischemic 
core <70mL 
CTP and NCCT 
ASPECTS 
criteria (modi-
fied protocol) ASPECTS 6-10 Not used ASPECTS 6-10 
Clinical Criteria 
Age (years) ≥18 ≥18 ≥18 
18-85 (later 
amended to 18-
80)   
18-80 (later 
amended to 
allow 81-85 if 
ASPECTS>8) 18-80 ≥18 
Baseline 
Stroke Severi-
ty NIHSS ≥2 NIHSS ≥6 No limit NIHSS 8-29 NIHSS ≥6 NIHSS 10-25 NIHSS ≥6 
Time to ran-
domization 6 hours 12 hours 6 hours 6 hours 8 hours 5 hours 6 hours 
Definition of 
sICH 
Any ICH and 
≥4-point in-
crease NIHSS 
Any ICH 
judged to cause 
≥2-point in-
crease NIHSS 
PH2/SAH + ≥4-
point increase 
NIHSS 
Any 
PH/SAH/IVH + 
≥4-point in-
crease NIHSS 
PH2 + ≥4 point 
increase NIHSS 
Any ICH and 
≥4-point in-
crease NIHSS 
PH2 + ≥4 point 
increase NIHSS 
Control Group 
 Standard care Standard care 
Standard care in 
IV alteplase 
eligible patients  
Standard care in 
IV alteplase 
eligible patients Standard care 
Standard care in 
IV alteplase 
eligible patients 
Standard care in 
IV alteplase 
eligible patients 
Intervention Group 
Wait for 
response to IV 
alteplase No No No No Yes No No 
Pre-specified 
time metrics No Yes No Yes Yes No No 
 10 
Type of Devic-
es Any Any Solitaire Solitaire Solitaire Any Any 
 
 
 
 
NCCT, Non contrast CT; CTA, CT angiography; CTP, CT Perfusion; MRI, Magnetic Resonance Imag-
ing; ICA, Internal Carotid Artery; MCA,  Middle Cerebral Artery; ASPECTS, Alberta Stroke Program 
Early CT Score; PH, Parenchymal Hemorrhage; SAH, Subarachnoid hemorrhage; IVH, Intra-ventricular 
Hemorrhage; NIHSS, National Institute of Health Stroke Scale; IV, intravenous. 
 
 
 
 
 
 
eTable 2: Endovascular treatment effect in patients with large ischemic core at baseline defined post-hoc 
using different ASPECTS scores on CT and/or MRI. 
 
Large extent of early ischemic change at 
baseline*  common Odds Ratio 95% Confidence Interval p-value 
ASPECTS 0 to 4 [n=126] 2.15 1.06 - 4.37 0.036 
ASPECTS 0 to 4 CT or 0 to 3 MR [n=105] 1.9 0.86 - 4.2 0.12 
ASPECTS 0 to 4 CT or 0 to 2 MR [n=89] 1.38 0.58 - 3.29 0.47 
ASPECTS 0 to 4 CT only [n=65] 1.68 0.58 - 4.87 0.34 
 
 
 
 
 
*Post-hoc definitions of large early ischemic change extent combining using different ASPECTS cut-
points for CT and MRI. Statistical significance is only obtained once all CT/MR data are used for AS-
PECTS 0-4. Since most MRI data are from one study (THRACE), we are not confident that one can reli-
ably distinguish MRI specific effect from a trial specific effect, especially among subgroups of this size. 
 
 
 
eTable 3: sICH numbers in patients who underwent EVT stratified by reperfusion status (mTICI>=2b or 
not) and ASPECTS categories 0-4. 
 
mTICI<2b mTICI>=2b 
ASPECTS 
sICH 
ASPECTS 
sICH 
No Yes Total No Yes Total 
0 1 0 1 0 0 1 1 
1 1 0 1 1 0 0 0 
2 2 0 2 2 3 0 3 
3 7 2 9 3 2 0 2 
4 1 4 5 4 21 2 23 
Total  12 6 18 Total  26 3 29 
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IV. STATISTICAL ANALYSIS PLAN 
A) Objective 
Endovascular treatment of acute stroke has been proven in randomized controlled trials as the standard of 
care for patients with proximal anterior circulation occlusions. This new evidence in the treatment of 
acute large vessel ischemic stroke has created a need for effective and rapid selection of stroke patients 
who will most benefit from endovascular stroke therapy.  
Imaging features have been proven to play a role in clinical outcome. We want to take advantage of the 
data accumulated through the different clinical trials to study if there are chances to improve the imaging 
protocol to adequately select patients that will benefit endovascular treatment.  
From the Hermes (Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials) neu-
roimaging studies of all patients in the MR CLEAN, ESCAPE, REVASCAT, SWIFT PRIME, EXTEND 
IA, PISTE and THRACE trials, we propose to determine whether imaging features at baseline that meas-
ure extent of parenchymal involvement, thrombus and collaterals are associated with response to endo-
vascular treatment. We also seek to extend safety information by looking for subgroups of patients (iden-
tified using imaging) who may a higher risk of complications from endovascular therapy. 
B) Imaging variables 
Parenchymal Imaging 
a) ASPECTS on non-contrast CT read blinded to other baseline imaging modalities.  
We will attempt analysis based on pre-specified ASPECTS categories, namely, 8-10, 5-7 and 0-
4. If sample size is sufficient across all ASPECTS grades, we will also attempt analysis by each 
ASPECTS grade i.e. 0,1,2,3,4,5,6,7,8,9,10 to identify an ASPECTS cut-point that suggests to fu-
tility of endovascular treatment. The majority of baseline imaging in the HERMES data is non-
contrast CT. When MRI is the baseline imaging modality, ASPECTS will be defined on baseline 
DWI. A region will be considered as involved if DWI lesion affects > 30% of the ASPECTS re-
gion.  
b) Extent of early ischemic change in the MCA territory dichotomized as > or < 33% MCA terri-
tory. 
 
Thrombus Imaging 
a) Location and nature of baseline thrombus on CTA (or if CTA not available on MRA). 
We will attempt analysis based on pre-specified baseline occlusion categories i.e. (ICA, proxi-
mal M1 MCA, distal M1 MCA, M2 MCA and beyond). M1 MCA segment is defined as the first 
branch of the intracranial ICA which courses horizontally from its branching point off the ICA 
through the sphenoidal section of the Sylvian fissure up to the first bifurcation distal to the origin 
of the lenticulostriate arteries in the distal aspect of the sphenoidal Sylvian fissure. The M2 
MCA segment was defined as distal to the MCA bifurcation and into the operculo-insular seg-
ment of the Sylvian fissure. Tandem occlusion was defined by CTA/MRA as occlusion of 
extracranial ICA with intracranial (ICA, M1-MCA, M2-MCA). 
b) Hyperdense artery sign presence, location and extent on non-contrast CT. Differential out-
comes will be reported by above categories. 
c) Clot burden score (CBS) on CTA (or if CTA unavailable, on MRA). The CBS is a scoring sys-
tem to define the extent of thrombus found in the proximal anterior circulation by location and 
is scored on a scale of 0–10. The thrombus can be partially or completely occlusive. A score of 
10 is normal, implying clot absence. A score of 0 implies complete multi-segment vessel oc-
clusion.  
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Collateral Circulation Imaging 
Collateral imaging is best done on multi-phase CTA or if not available, on appropriately phase weighted 
single-phase CTA. Analysis of collateral status and its relationship to final outcomes by treatment arm 
will be reported for pre-specified collateral grade categories: Grade 0-1 poor, grade 2: intermediate and 
grade 3: good as well as in a granular manner for each category.  
         C) Primary Outcome 
The modified Rankin Scale (mRS) at 3 months from onset. 
        D) Secondary Outcomes   
Secondary efficacy outcomes were functional independence (mRS 0–2) at 90 days, excellent functional 
outcome (mRS 0–1) at 90 days, dramatic neurological improvement (defined as neurological improve-
ment of ≥ 8 points in the NIHSS or a NIHSS 0-1 24 hours after stroke) and patients in the endovascular 
group with complete arterial recanalization [defined as a modified Thrombolysis In Cerebral Infarction 
(mTICI) score 2b or 3]. Safety outcomes included the symptomatic intracranial hemorrhage (sICH; de-
fined by each trial), parenchymal hematoma type 2 (PH2; blood clot occupying >30% of the infarcted 
territory with substantial mass effect) within 5 days of randomization, and mortality within 90 days. 
E) Primary Analyses  
All analyses will be based on the “as randomized” population. To account for between trial differences 
when pooling patient level data, mixed-effects modeling will be used for all analyses, with fixed effects 
for parameters of interest and “trial” and the interaction term “trial*treatment” as random effects variables 
in all models. Regression models will include fixed effects (age, sex, NIHSS score at admission, intrave-
nous alteplase use and time from onset to randomization) and multiplicative interaction terms to test if 
pre-specified baseline-imaging features modified the effect of treatment allocation on pre-defined out-
comes. The primary analyses will try to ascertain if baseline imaging categorization modifies the effect of 
treatment on mRS at 90 days when adjusted for pre-specified co-variates. Primary analysis will use ordi-
nal logistic regression adjusted for age, sex, NIHSS score at admission, intravenous alteplase (yes/no) and 
time from onset to randomization. It will include interaction terms testing if imaging categorization at 
baseline (parenchymal imaging, thrombus imaging and collateral imaging independently) modifies the 
relationship between treatment and outcome. If statistically significant interaction is noted, category spe-
cific effects will be reported (in text and using figures). 
F) Secondary Analysis  
Depending on the nature and distribution of secondary outcomes specified above, secondary analyses will 
use appropriate regression techniques adjusted for age, sex, NIHSS score at admission, intravenous 
alteplase (yes/no) and time from onset to randomization to analyze if the above-defined imaging catego-
ries modify the effect of treatment on outcome. Multiplicative interaction terms will be used to test for 
these statistical interactions. If statistically significant interaction is noted, category specific effects will 
be reported (in text and using figures). For primary and secondary analyses, forest plots with each imag-
ing category specific effect including interaction p value will be reported.  
Sensitivity analyses as above will be performed for patients imaged using CT vs. MRI. 
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data. 
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Structured 
summary 
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pants, interventions, comparators and outcomes. 
Methods: report eligibility criteria; data sources including dates of last bibliographic 
search or elicitation, noting that IPD were sought; methods of assessing risk of bias. 
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Objectives 4 Provide an explicit statement of the questions being addressed with reference, as appli-
cable, to participants, interventions, comparisons, outcomes and study design (PICOS). 
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tion information including registration number and registry name. Provide publication 
details, if applicable. 
Previous SAP is stated in page 6 and included as an 
appendix 
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Not applicable 
If applicable, describe how any studies for which IPD were not available were dealt with. 
This should include whether, how and what aggregate data were sought or extracted 
from study reports and publications (such as extracting data independently in duplicate) 
and any processes for obtaining and confirming these data with investigators. 
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Manuscript reference number: THELANCETNEUROLOGY-D-18-00326. 
 5 
Results 
Study selection 
and IPD ob-
tained 
17 Give numbers of studies screened, assessed for eligibility, and included in the systematic 
review with reasons for exclusions at each stage. Indicate the number of studies and 
participants for which IPD were sought and for which IPD were obtained. For those stud-
ies where IPD were not available, give the numbers of studies and participants for which 
aggregate data were available. Report reasons for non-availability of IPD. Include a flow 
diagram. 
 6 and e figure 1 in the supplement  
Study character-
istics 
18 For each study, present information on key study and participant characteristics (such as 
description of interventions, numbers of participants, demographic data, unavailability 
of outcomes, funding source, and if applicable duration of follow-up). Provide (main) 
citations for each study. Where applicable, also report similar study characteristics for 
any studies not providing IPD. 
6 and Table1 
IPD integrity A3 Report any important issues identified in checking IPD or state that there were none.  6 and e figure 1 in the supplement  
Risk of bias with-
in studies 
19 Present data on risk of bias assessments. If applicable, describe whether data checking 
led to the up-weighting or down-weighting of these assessments. Consider how any 
potential bias impacts on the robustness of meta-analysis conclusions.  
6 
Results of indi-
vidual studies 
20 For each comparison and for each main outcome (benefit or harm), for each individual 
study report the number of eligible participants for which data were obtained and show 
simple summary data for each intervention group (including, where applicable, the 
number of events), effect estimates and confidence intervals. These may be tabulated or 
included on a forest plot.   
N/A 
Manuscript reference number: THELANCETNEUROLOGY-D-18-00326. 
 6 
Results of syn-
theses 
21 Present summary effects for each meta-analysis undertaken, including confidence inter-
vals and measures of statistical heterogeneity. State whether the analysis was pre-
specified, and report the numbers of studies and participants and, where applicable, the 
number of events on which it is based.  
6-7 , Figure 1, Figure 2, Table 2, Figure 3, 
Table 3, Supplement eFigure 9, Supplement 
eFigure 10. 
When exploring variation in effects due to patient or study characteristics, present 
summary interaction estimates for each characteristic examined, including confidence 
intervals and measures of statistical heterogeneity. State whether the analysis was pre-
specified. State whether any interaction is consistent across trials.  
Provide a description of the direction and size of effect in terms meaningful to those 
who would put findings into practice. 
Risk of bias 
across studies 
22 Present results of any assessment of risk of bias relating to the accumulated body of 
evidence, including any pertaining to the availability and representativeness of available 
studies, outcomes or other variables. 
7-8 
Additional anal-
yses 
23 Give results of any additional analyses (e.g. sensitivity analyses). If applicable, this should 
also include any analyses that incorporate aggregate data for studies that do not have 
IPD. If applicable, summarise the main meta-analysis results following the inclusion or 
exclusion of studies for which IPD were not available. 
9 
Discussion 
Summary of 
evidence 
24 Summarise the main findings, including the strength of evidence for each main outcome. 8-9 
Strengths and 
limitations 
25 Discuss any important strengths and limitations of the evidence including the benefits of 
access to IPD and any limitations arising from IPD that were not available. 
8-9 
Manuscript reference number: THELANCETNEUROLOGY-D-18-00326. 
 7 
Conclusions 26 Provide a general interpretation of the findings in the context of other evidence. 8-9 
Implications A4 Consider relevance to key groups (such as policy makers, service providers and service 
users). Consider implications for future research. 
8-9 
Funding 
Funding 27 Describe sources of funding and other support (such as supply of IPD), and the role in 
the systematic review of those providing such support. 
7 
 
 
 
A1 – A3 denote new items that are additional to standard PRISMA items. A4 has been created as a result of re-arranging content of the standard PRISMA statement to 
suit the way that systematic review IPD meta-analyses are reported.  
© Reproduced with permission of the PRISMA IPD Group, which encourages sharing and reuse for non-commercial purpose 
Response to Review Manuscript reference number: THELANCETNEUROLOGY-D-
18-00326R3 
Editorial points: 
 
Editorial points to be addressed: 
 
1. Please provide the missing signatures for the following authors: 
 
Maria Hernandez Perez 
Antoni Davalos 
Charles Majoie 
Jeffrey Saver 
Demetrius Lopes 
Carlos Molina 
Vivek Reddy 
Alim Mitha 
Erik Cobo 
Gary Ford 
 
RESPONSE: We have provided them  excepting  Dr Reddy´s  who has been excluded as 
an author by not contributing with  his signature for this article 
 
 
 
 
2. Please include a statement of authors' contributions and a statement on au-
thors' declarations of interests in your revised manuscript. Please note, these 
statements should match the information provided on the submitted forms 
 
 
RESPONSE: We have included statement of authors' contributions and a statement on 
authors' declarations of interests in the manuscript  
 
3. Please amend your abstract to include the primary safety outcome. 
 
RESPONSE: We have made changes as suggested  
 
*Reply to Reviewers Comments
